20 Slash 20 Inc., the creator of The Eye Drink, the world's first ready-to-drink functional beverage designed to combat screen-induced eye issues, was featured at the Moody Capital Solutions 2026 Disruptive Growth and Life Sciences Conference. The conference, which showcases companies at the forefront of disruptive innovation, provided a platform for 20 Slash 20 to present its novel approach to preventive eyecare.
The Eye Drink is formulated for individuals who spend prolonged hours in front of computer or smartphone screens, aiming to minimize dry eyes and potential macular damage. Its formula includes science-backed nutrients derived from AREDS 2 studies and vegan-friendly Omega-3 in triglyceride form, which are known to support visual performance and ocular comfort. By combining clinical science with a convenient beverage format, 20 Slash 20 is making preventive eyecare accessible and enjoyable.
The company distributes The Eye Drink through direct-to-consumer channels, professional medical affiliates, and natural product retail stores. This multi-channel approach allows 20 Slash 20 to reach a broad audience, from tech professionals to health-conscious consumers, positioning itself as a modern solution to a growing public health concern.
The conference, organized by Moody Capital Solutions, an independent investment bank with over 40 years of experience, brings together emerging growth companies and investors. IBN, a multifaceted financial news and publishing company, provided coverage of the event through its custom-built portal, offering summaries of participating companies and enabling investors to access market research tools and company websites. IBN's coverage extends to social media and syndicated articles, maximizing the visibility of the event and its participants.
The significance of this announcement lies in the increasing prevalence of digital eye strain and related ocular issues in today's society. As screen usage continues to rise, the demand for products that address these concerns is expected to grow. 20 Slash 20's Eye Drink represents a proactive approach to eye health, potentially setting a new standard in the functional beverage market. By presenting at this conference, the company is not only showcasing its product to potential investors but also highlighting the importance of integrating clinical research into everyday consumer products.
For more information about 20 Slash 20 and The Eye Drink, visit the company's website at theeyedrink.com. To learn more about the conference and its participants, visit Moody Capital's conference page. IBN's coverage of the event can be accessed at IBN's conference coverage.
As the world becomes increasingly digital, innovations like The Eye Drink may become essential in preserving vision and enhancing quality of life. The attention garnered from this conference underscores the growing market for functional beverages that address specific health needs, paving the way for further advancements in the field.
